Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics, Inc. announced novel immunological biomarker data from its ongoing Phase 2 PrTK05 trial for patients with intermediate-risk localized prostate cancer, showing T-cell activation and evidence of persistent local immune remodeling. The company plans to include biodistribution and shedding data from this trial in its Biologics License Application (BLA) submission to the FDA, expected in Q4 2026. The intermediate-risk prostate cancer patient population represents a significant market, with approximately 65,000 patients treated annually in the U.S.